Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;32(1):155-73.
doi: 10.1016/j.cger.2015.08.010.

Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly

Heidi D Klepin  1
Affiliations
Review

Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly

Heidi D Klepin. Clin Geriatr Med. 2016 Feb.

Abstract

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic diseases that frequently affect older adults. Treatment is challenging. Management of older adults with MDS and AML needs to be individualized, accounting for both the heterogeneity of disease biology and patient characteristics, which can influence life expectancy and treatment tolerance. Clinical trials accounting for the heterogeneity of tumor biology and physiologic changes of aging are needed to define optimal standards of care. This article highlights key evidence related to the management of older adults with MDS and AML and highlights future directions for research.

Keywords: Acute myeloid leukemia; Elderly; Management; Myelodysplasia; Older; Treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative survival by time and age for Acute Myeloid Leukemia
See this image and copyright information in PMC

References

    1. Efficace F, Gaidano G, Breccia M, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. British journal of haematology. 2015;168:361–370. - PubMed
    1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52. - PubMed
    1. SEER Cancer Statistics Review 1975-2009. 2012 http://seercancergov/publications/
    1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088. - PubMed
    1. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465. - PMC - PubMed

Publication types